Report reflects good and bad of Paion's Cosmo deal

6 July 2016
paion-large

Investment research firm Edison has raised its valuation on German specialty pharma company Paion (ETR: PA8) but decreased the earnings per share (EPS) assessment after the out-licensing of certain rights to Italian drugmaker Cosmo Pharmaceuticals (SIX: COPN).

Figures quoted in the report reflect the impact on Paion’s value of the sale of the US rights to the short-acting anaesthetic remimazolam, the company’s lead product, which is undergoing Phase III trials in the USA.

The deal with Cosmo brings Paion 20 million euros ($22.2 million) of cash, including a 9.6 million euros share purchase, 42.5 million euros in potential milestones and a 20% to 25% royalty.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical